Regional Meetings 2020

Novel and Emerging Therapeutic Strategies in the Management of Select Gastrointestinal Cancers — An Interactive Grand Rounds Series

Research To Practice (RTP) is pleased to offer community- and academic-based hospitals and cancer centers throughout the United States the opportunity to participate in an interactive live educational activity focused on the management of select gastrointestinal cancers. Each session in this regional series will feature a blend of didactic presentation, discussion of steering committee members’ treatment recommendations, interactive polling of attendees using keypad devices and follow-up audience Q&A.

If you are interested in hosting a session at your institution, please email our Meeting Services Department at or call (800) 233-6153.

Learn about our other interactive Grand Rounds CME series:

Schedule of Events:

Thursday, January 16, 2020
6:00 PM – 7:00 PM
Education program

Philip A Philip, MD, PhD
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana

Buffet dinner will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
There is no registration fee for these events. However, preregistration is advised as seating is limited.

Each 1-hour session will include 4 topic modules focused on the current management of 4 distinct GI cancers and will endeavor to review available emerging research data and provide perspectives on the optimal integration of novel agents and strategies into established treatment algorithms. Each event will employ an identical format that will include the following elements:

  • Discussion of Steering Committee Members’ Treatment Recommendations
  • Review of Available Clinical Research Findings
  • Integration of Interactive Audience Polling Results
MODULE 1 Colorectal cancer: Long-term management of metastatic disease; role of checkpoint inhibitors for microsatellite instability-high tumors MODULE 2 Pancreatic cancer: Neoadjuvant and adjuvant treatment options; integration of nal-IRI into current therapeutic algorithms and emerging data with PARP inhibitors MODULE 3 Hepatocellular carcinoma: Approved and investigational treatment approaches for metastatic disease MODULE 4 Gastric cancer: Optimal selection and sequencing of therapies in the metastatic setting; novel agents under investigation

Each session will conclude with a 5-minute Q&A segment


Tanios Bekaii-Saab, MD
Professor, Mayo Clinic College of Medicine
and Science
Program Leader, Gastrointestinal Cancer
Mayo Clinic Cancer Center
Vice-Chair and Section Lead, Division of
Medical Oncology
Medical Director, Cancer Clinical Research Office
Senior Associate Consultant
Mayo Clinic
Phoenix, Arizona

Johanna Bendell, MD
Chief Development Officer
Director, Drug Development Unit Nashville
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Howard S Hochster, MD

Distinguished Professor of Medicine
Rutgers Robert Wood Johnson Medical School
Rutgers-CINJ Associate Director, Clinical Research
Director, Clinical Oncology Research
RWJBarnabas Health
New Brunswick, New Jersey

John L Marshall, MD
Chief, Hematology and Oncology
Director, Ruesch Center for the Cure of GI Cancers
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Wells A Messersmith, MD
Professor and Head, Division of Medical Oncology
Associate Director for Translational Research
University of Colorado Cancer Center
Aurora, Colorado

Eileen M O’Reilly, MD
Winthrop Rockefeller Chair in Medical Oncology
Section Head
Hepatopancreaticobiliary/Neuroendocrine Cancers
Gastrointestinal Oncology Service
Associate Director
David M Rubenstein Center for Pancreatic Cancer
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Philip A Philip, MD, PhD
Kathryn Cramer Endowed Chair in Cancer Research
Professor of Oncology and Pharmacology
Leader, GI and Neuroendocrine Oncology
Vice President of Medical Affairs
Karmanos Cancer Institute
Wayne State University
Detroit, Michigan

Alan P Venook, MD
The Madden Family Distinguished Professor of
Medical Oncology and Translational Research
Shorenstein Associate Director
Program Development
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Project Chair

Neil Love, MD
Research To Practice
Miami, Florida

Target Audience:
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of gastrointestinal (GI) cancer.

Learning Objectives:

  • Review recent therapeutic advances and related FDA authorizations for patients with newly diagnosed and relapsed or recurrent colorectal, gastric, hepatocellular and pancreatic cancer, and integrate this information, as appropriate, into routine clinical practice.
  • Recall the biologic rationale for, published research data with and ongoing research efforts evaluating the use of immune checkpoint inhibitors in the management of gastrointestinal (GI) cancers, and identify patients who may be eligible for this strategy as part or outside of a protocol setting.
  • Appreciate available data with and consider the potential clinical roles of a number of approved and novel agents (eg, cabozantinib, lenvatinib, ramucirumab, TAS-102) that may provide treatment options to patients with diseases beyond those for which they were initially indicated.
  • Design and implement a plan of care to recognize and manage side effects and toxicities associated with novel and recently approved systemic therapies for locally advanced or metastatic colorectal, gastric, hepatocellular and pancreatic cancer to support patient quality of life and continuation of therapy.
  • Recall available and emerging data with other investigational agents currently in clinical testing for GI cancers, and where applicable, refer eligible patients for trial participation or other expanded access programs.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Commercial Support:
These activities are supported by educational grants from Bayer HealthCare Pharmaceuticals, Celgene Corporation, Eisai Inc, Lilly and Taiho Oncology Inc.